Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs
Articolo
Data di Pubblicazione:
2023
Citazione:
Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs / A. Romandini, D. Baldassarre, S. Genovese, S. Capri, G. Pompilio, M. Scatigna, J. Pablo Werba. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 16:2(2023), pp. 176.1-176.17. [10.3390/ph16020176]
Abstract:
Innovative lipid-modifying agents are valuable resources to improve the control of athero-
genic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intol-
erance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe).
Moreover, some of the upcoming compounds potently affect lipid targets that are thus far considered
“unmodifiable”. The present paper is a viewpoint aimed at presenting the incremental metabolic and
cardiovascular benefits of the emerging lipid-modulating agents and real-life barriers, hindering their
prescription by physicians and their assumption by patients, which need to be worked out for a more
diffuse and appropriate drug utilization.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Atherogenic dyslipidemia; lipid-modifying drugs; cardiovascular disease; drug intolerance
Elenco autori:
A. Romandini, D. Baldassarre, S. Genovese, S. Capri, G. Pompilio, M. Scatigna, J. Pablo Werba
Link alla scheda completa: